Travere Therapeutics (TVTX) Current Leases (2020 - 2026)

Travere Therapeutics has reported Current Leases for 7 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 10.2% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 10.2% YoY), and the FY2025 full-year result was $5.9 million, up 8.7% from the prior year.
• Current Leases for Q1 2026 stood at $6.0 million, up from $5.9 million in the prior quarter.
• The five-year high for Current Leases was $6.0 million in Q1 2026, with the low at $4.0 million in Q1 2022.
• Historically, Current Leases has averaged $5.0 million across 5 years, with a median of $5.0 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases rose 13.43% — and 2025, when it increased 8.25%.
• Travere Therapeutics' Current Leases stood at $4.4 million in 2022, then rose by 10.74% to $4.9 million in 2023, then grew by 10.1% to $5.4 million in 2024, then grew by 8.7% to $5.9 million in 2025, then grew by 2.42% to $6.0 million in 2026.
• The last three Current Leases figures came in at $6.0 million (Q1 2026), $5.9 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.